This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About

Burden of Disease

Burden of Disease

Description of the DiseaseGlobal EpidemiologyIndian EpidemiologyPneumococcal Disease and InfluenzaChallenges

Risk Factors
 

Risk Factors

Secondary Infections
​​​​​​​

Secondary Infections

Mechanism of Action
​​​​​​​

Mechanism of Action

Prevention of Pneumococcal Disease
 

Polysaccharide VaccineConjugate VaccineDifference

Need for Pneumococcal Vaccination

In ElderlyIn India

Cost-effectiveness of PCV13
 

NeedIndian StudiesGlobal Studies

Legacy of Prevenar
 

ManufacturingCRM197Activation and ConjugationPneumococcal Disease and InfluenzaDistributionVideos

Safety
 

Safety

Conclusion
 

Conclusion
Dosing

Dosing
 

Adults ≥18 Years of AgeAdults ≥50 Years of AgeCOVID VaccinationFlu Vaccination
Efficacy

Prevenar 13® Clinical Experience
 

IntroductionClinical Trials

Efficacy of Prevenar 13®
 

IntroductionStudyObjectiveMethodologyCriteriaResultsConclusion

Effectiveness of Prevenar 13® 
 

IntroductionObjectiveMethodologyAnalysisResultsLimitationsLearningsConclusion

Indian Clinical Trials
 

IntroductionStudy DesignResultsLimitationsConclusion
Recommendations for Use

Recommendations for Use
 

ACIP 2019NCCN 2020RSSDI 2020IMA GuidelinesIAOH Guidelines for Working AdultsClinical Practice Guidelines 2019 (ICS/NCCP)The Geriatric Society of India, 2015Indian Society of Nephrology
FAQs

PCV13 in Pulmonology
 

RoleComplicationsClinical DataRecommendations

PCV13 in Nephrology
 

RoleClinical DataRecommendations

PCV13 in Oncology
 

RoleClinical DataRecommendations

PCV13 in Rheumatology
 

RoleComplicationsDataRecommendationsConsensus

PCV13 in Diabetes
 

RoleComplicationsDataRecommendations

PCV13 in HIV Infection
 

RoleBurdenPulmonary InfectionDataEfficacyRecommendations

PCV13 in Cardiology
 

RoleBurdenComplicationsDataRecommendations
Resources

Resources

Summary of Prescribing InformationDownloadable ResourcesEvents and WebinarsLatest Articles

Clinical Data

Pneumococcal Infections in Solid and Haematological Malignancies, and Bone Marrow Transplant Recipients: Clinical and Immunogenicity Data of Pneumococcal Vaccines

   

A systematic review of 26 studies on the safety and efficacy of pneumococcal vaccines in oncohaematological patients revealed that PCV13 vaccination is well tolerated in patients with CLL, and provokes an effective immune response in considerable proportion of these patients. For attaining an optimal immune response, use of PCV13 is recommended as early as possible following CLL diagnosis.1 A study evaluated the effect of a system base intervention of providing PCV13 before initiating chemotherapy and/or biological treatment. As a result of the intervention, a 35% decrease in the number of hospitalised patients with pneumonia or sepsis was observed. In addition, a significant trend towards a decrease in mortality pre-versus post-intervention was observed (11% vs. 7%).2

   

A randomised study by the Swedish CLL group assessed whether patients with untreated CLL benefit from PCV13 in terms of immune response, as compared with PPSV23. The results indicated that after 1 month of vaccination, PCV13 yielded superior immune response in 10/12 serotypes, as compared with PPSV23, and in 5/12 serotypes after 6 months of vaccination. Since the immune response of PCV13 was superior to that of PPSV23 in patients with previously untreated CLL, the study proposed that PCV13 should be included in the immunisation programmes for patients with CLL, and should be administered as early as possible following the diagnosis of the disease.3 Previously, a study investigated the antibody persistence in patients with CLL after pneumococcal conjugate vaccination. Five years after vaccination with PCV7, the percentage of patients with CLL with antibody levels that provide protection against IPD ranged between 29% and 71%. These results indicated that PCVs result in antibody persistence, at least for 5 years in patients with CLL.4   

   

A prospective cohort study evaluated response to PCV13 in patients with multiple myeloma as compared with healthy controls. The study enrolled 7 patients with multiple myeloma and 18 control subjects. Apart from assessing the initial response to PCV13, the study also compared the durability of response at 6 months following vaccination. The findings revealed that PCV13 elicits similar initial immune response in both patients with multiple myeloma and control subjects. However, the duration of the response might diminish in patients with multiple myeloma when compared with healthy subjects.5

   

Pneumococcal Infections in Solid and Haematological Malignancies, and Bone Marrow Transplant Recipients: Clinical and Immunogenicity Data of Pneumococcal Vaccines   

   

A retrospective study performed in Paris over a period of 3 years, from January 2004 to December 2006, evaluated the serotype distribution of S. pneumoniae in 25 consecutive pneumococcal infections in oncohaematology and HSCT patients. The serotype coverage by PCV13, PPSV23 and PCV7 were found to be 84%, 92% and 76%, respectively.6 In a small open randomised study, as compared with PPSV23, PCV13 led to a better response in patients with B-cell lymphoma, 12 months after rituximab treatment.3 A study on 24 previously untreated patients with CLL revealed that PCV13 is well tolerated and effective (58.3% immune response) in these patients, and for achieving optimal vaccination response, PCV13 is recommended to be administered as soon as possible following diagnosis.7   

   

Clonal proliferation of differentiated plasma cells leads to MGUS, which is measured by serum concentration of the M-protein. Since MGUS patients have increased risk of developing infections, pneumococcal vaccines are recommended for patients with such lymphoproliferative disorders. Pasiarski et al. evaluated the immune response to PCV13 in treatment-naïve MGUS patients as compared with healthy subjects. The study reported that PCV13 is well tolerated and effective in MGUS patients, and in case of unvaccinated MGUS patients, immunisation with PCV13 should be done as early as possible following diagnosis. In MGUS patients, concentration of serum M-proteins could be a useful predictor of PCV13 effectiveness since the study revealed that PCV13 vaccination is more effective in patients with lower M-protein concentration.8   

   

A prospective randomised controlled trial evaluated whether administering PCV13 on the first day of chemotherapy is non-inferior to its use 2 weeks before chemotherapy initiation, in adult patients with solid malignancies. No significant difference was observed when patients were vaccinated on the first day of chemotherapy, or 2 weeks prior to chemotherapy initiation. During adjuvant chemotherapy, adequate overall antibody response to PCV13 was observed in both patients with gastric and colorectal cancer.9   

   

Patients with SCD, a common inherited haematological disorder, are also at increased risk of IPD, and are dependent on pneumococcal vaccination for the prevention of infection. A study evaluated the immunogenicity of PCV7 (prior to PCV13 introduction) followed by PPSV23 administered at 2 and 5 years of age and then every 5 years thereafter, in patients with SCD. The results revealed that a sufficient immune response to PPSV23 was not maintained up to 5 years in a significant proportion of patients with SCD. At an average of 37 months following vaccination, only 36% of patients had protective levels of anti-pneumococcal antibody titres. The study concluded that this vaccination strategy may not lead to optimum maintenance of anti-pneumococcal immunity in patients with SCD.10  

   

   

CLL, chronic lymphocytic leukaemia; HSCT, haematopoietic stem cell transplant; IPD, invasive pneumococcal disease; MGUS, monoclonal gammopathy of undetermined significance; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; SCD, sickle cell disease.

References:

La Torre G, Mannocci A, Colamesta V, D'Egidio V, Sestili C, Spadea A. Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness, and safety. Mediterr J Hematol Infect Dis. 2016;8(1):e2016044.Draliuk R, Mintsman I, Shnaider A, et al. Pneumococcal vaccination (PCV13) prior to initiation of immunosuppressive therapy in patients with hematological malignancies is associated with decrease morbidity and decrease hospitalizations. Blood. 2018;132(Suppl 1):5919.Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. A randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701-3707.Lindström V, Aittoniemi J, Salmenniemi U, et al. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2018;14(6):1471-1474.Mustafa SS, Shah D, Bress J, Jamshed S. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Hum Vaccin Immunother. 2019;15(2):452-454.Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009;15(9):865-868.Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients – preliminary report. PLoS One. 2014;9(12):e114966.Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance - relationship with selected immune and clinical parameters. Clin Interv Aging. 2019;14:1741-1749.Choi W, Kim JG, Beom SH, et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial. Cancer Res Treat. 2020;52(1):246-253.Santoro JD, Myers L, Kanter J. Assessing the immunogenic response of a single center’s pneumococcal vaccination protocol in sickle cell disease. J Pediatr Hematol Oncol. 2016;38(3):e102-e106.

   

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

   

PP-PRV-IND-0268 July 2022

PCV13 in Oncology

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more


Efficacy

Efficacy proven by the CAPiTA study

Learn more


Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-PRV-IND-0268

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022